The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.
DailyMed lists Structured Product Labeling version 9 for the reviewed Linaclotide label family with a published date of 2015-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206127 with status AP dated 2015-12-08, and names eptifibatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 8 for the reviewed Linaclotide label family with a published date of 2015-12-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 13 for the reviewed Dulaglutide label family with a published date of 2015-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2015-22673, attributed to FDA and its parent HHS department, on 2015-09-09. Its official title is “Determination That GLUCAGON (Glucagon Hydrochloride) for Injection, Equivalent to 1 Milligram Base/Vial and Equivalent to 10 Milligram Base/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090811 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090816 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090854 with status AP dated 2015-06-12, and names eptifibatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 12 for the reviewed Dulaglutide label family with a published date of 2015-06-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091555 with status AP dated 2015-06-05, and names eptifibatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 201831 with status AP dated 2015-05-28, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 201849 with status AP dated 2015-05-08, and names glucagon hydrochloride among the application record's active ingredients.
The Federal Register published notice 2015-10994, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.
The Federal Register published notice 2015-11000, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.
The Federal Register published notice 2015-11003, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.
The Federal Register published notice 2015-09299, attributed to FDA and its parent HHS department, on 2015-04-22. Its official title is “Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 3 for the reviewed Pramlintide label family with a published date of 2015-03-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 11 for the reviewed Dulaglutide label family with a published date of 2015-03-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Pramlintide label family with a published date of 2015-03-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 10 for the reviewed Dulaglutide label family with a published date of 2015-01-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 1 for the reviewed Pramlintide label family with a published date of 2015-01-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 8 for the reviewed Dulaglutide label family with a published date of 2015-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.